Epigenetics: Market Research Report

February 2010 | 361 pages | ID: E8CED9AE1C9EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the Global market for Epigenetics in US$ Million by the following Application Areas: Drug Discovery, Diagnostics, and Others.

Annual forecasts are provided for the period 2006 through 2015.

The report profiles 39 companies including many key and niche players worldwide such as Celgene Corporation, CellCentric Ltd., CellCentric Ltd., Epigentek Group, Inc., Genpathway, Inc., Merck & Co., Inc., MGI Pharma, Inc., Millipore Corporation, OncoMethylome Sciences S.A., and Orion Genomics.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Epigenetics: An Introduction
Cancer: The Key Focus Area for Epigenetics
Histone Changes as Biomarkers: An Emerging Field
Future of Epigenetics

2.GLOBAL MARKET OVERVIEW

Scope of Epigenetics
Oncology
Psychiatry
Outlook of Epigenetic Treatments
Current and Future Analysis
Market Segmentation
Therapeutics
Diagnostics
Research Tools
Epigenetics Stretching to hESC Research
Epigenetics: Transforming from Special Niche to Widespread Collection of Tools
Pros and Cons of First Generation Epigenetics Drugs
Advances in Epigenetics Technologies, Therapeutics and Diagnostics
Outlook for Product Positioning and Innovation
Epigenetic Community Initiatives
Patent Law in Japan

3.COMPETITION

Epigenomics Pioneers the Epigenetics Diagnostics
Merck Leads HDAC Inhibitors Market
Huge Potential for Novel Therapies
Combination Therapy
Novel Technologies

4.PRODUCT OVERVIEW

Epigenetics - Definition
Categories of Signals in Epigenetics
Introduction
Etymology and Meaning
Epigenetics - Molecular Base
Mechanisms
Chromatin Remodeling and DNA Methylation
RNA Transcripts and Programmed Proteins
Prions
Structural Inheritance Systems
Functions and Outcomes
Development
Medicine
Evolution
Epigenetics in Microorganisms

5.PRODUCT LAUNCHES

Epigentek Group Launches New Measures for DNA Methylation Shifts
QIAGEN Introduces EpiTect® HRM™ PCR Kit
Enzo Biochem Rolls Out Wide-Ranging Epigenetics Tools
Applied Biosystems Unveils Novel Small RNA Expression Analysis Solution
Sigma-Aldrich Launches Imprint™ Methylated DNA Quantification Kit
Sigma-Aldrich Unveils ChIP Kit for Epigenetic Research
Pyrosequencing Introduces New PyroMark™ Q24
Qiagen Expands Epitect Portfolio
Applied Biosystems Introduces New SOLiD™ 3 System

6.RECENT INDUSTRY ACTIVITY

Merck Merges with Schering-Plough
Celldex Therapeutics Acquires CuraGen
NCCN Upgrades Vidaza to Category 1
PrognosDx Health Obtains UCLA Epigenetics Technology Rights
PROGEN Posts Positive Results from Preclinical Epigenetics Product
Pharmacyclics Announces Positive Scientific Results from PCI-24781 Clinical Trial Targeting HDAC
CellCentric Signs Agreement with Takeda
Orion Genomics and Novartis Ink Multi-Year Collaboration and License Agreement
SuperGen Collaborates with GlaxoSmithKline
QIAGEN to Acquire SABiosciences
QIAGEN Takes Over DxS
CellCentric Expands Number of Researchers
Roche NimbleGen Enters into Collaboration with Sigma-Aldrich
Quest Diagnostics Gains biomarker license from Epigenomics
Babraham Institute Launches New Epigenomics Sequencing Facility
Active Motif Enters into Licensing Agreement with City of Hope
NIH to Grant US$62 Million for Epigenetic Research
Rush University Medical Center Obtains US$5.5 Million Grant from NIH
Celgene Takes Over Pharmion
Eisai Takes Over MGI PHARMA
Affymetrix Acquires Panomics
QIAGEN Takes Over Biotage’s Biosystems
Millipore Corporation and Agilent Technologies Collaborate
Invitrogen Signs License Agreement with Genisphere
Invitrogen and IMBcom Proprietary Ink Licensing Agreement
OncoMethylome Sciences and QIAGEN Sign Licensing Agreement
Pharmacyclics Characterizes Highly Selective HDAC Inhibitor
Celgene’s Vidaza Gains Approval for MDS and AML in Europe
Medistem Enters into Epigenetics Collaboration
Orion Geomics Obtains License for IGF2 Gene from Johns Hopkins
Progen Pharmaceuticals Acquires CellGate
BioServe Purchases Genomics Collaborative
Sigma-Aldrich and Epigentek Signs Licensing Agreement
Constellation Pharmaceuticals and BioTrove Enter into R&D Collaboration

7.RECENT RESEARCH FINDINGS

Salk Institute Researchers Present Full Epigenome Map
Baylor College of Medicine Recognizes Epigenetic Affects on Obesity
Prenatal Starvation Could Cause Epigenetic Modifications
John Hopkins Scientists Reveal Epigenetic Modifications Take Place Over Lifetime
Advances in Epigentic Regulation Focuses on Breast Cancer

8.FOCUS ON SELECT PLAYERS

Celgene Corporation (US)
CellCentric Ltd. (UK)
Epigenomics AG (Germany)
Epigentek Group, Inc. (US)
Genpathway, Inc. (US)
Merck & Co., Inc. (US)
MGI Pharma, Inc. (US)
Millipore Corporation (US)
OncoMethylome Sciences S.A (Belgium)
Orion Genomics (US)

9.GLOBAL MARKET PERSPECTIVE

Table 1. World Recent Past, Current & Future Analysis for Epigenetics by Application Area – Drug Discovery, Diagnostics and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 2. World 10-Year Perspective for Epigenetics by Application Area – Percentage Breakdown of Dollar Sales for Drug Discovery, Diagnostics, and Others Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 39 (including Divisions/Subsidiaries - 42)
Region/CountryPlayers
The United States
Canada
Japan
Europe
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)